Anti-IL1B Neutralizing Antibody (V3S-0622-YC1902)

Figure 1 Anti-IL1B Monoclonal Antibody (V3S-0622-YC1902) in SDS-PAGE
Figure 2 Anti-IL1B Monoclonal Antibody (V3S-0622-YC1902) in SEC-HPLC
Figure 3 Anti-IL1B Monoclonal Antibody (V3S-0622-YC1902) in WB
Figure 4 Anti-IL1B Monoclonal Antibody (V3S-0622-YC1902) in ELISA

Datasheet

MSDS

COA

Summary

Description	This product is a human monoclonal antibody that reacts with IL1B. The antibody is expressed with mammalian cell transient expression system, serum-free and purified by affinity chromatography. The purity and integrity are tested via SDS-PAGE and SEC-HPLC analysis. Given an antigen, additional QC measures are also desired such as affinity testing and binding validation. Specifically, the antibody is provided in multiple formats for in vivo and in vitro assays. The Invivo version features greater than 95% purity, ultra-low endotoxin levels (<1 EU/mg or 0.1 EU/mg), and is preservative, stabilizer, and carrier protein-free.
Clonality	Monoclonal
Host Species	Human
Target Species	Human
Immunogen	Recombinant human ILI beta
Isotype	IgG

Property

Expression Species	HEK293F or CHO
Conjugation	None
Purity	>95%, determined by SDS-PAGE and/or SEC-HPLC
Endotoxin	<1 EU/mg, determined by LAL method
Purification	Protein A affinity purified
Sterility	0.2 μM filtered
Formulation	PBS, pH 7.4
Preservation	No preservatives
Stabilizer	No stabilizers
Storage	Store at 4⁰C within a week. For longer storage, aliquot and store at -20⁰C.

Tested Data

SDS-PAGE

Figure 1 Anti-IL1B Monoclonal Antibody (V3S-0622-YC1902) in SDS-PAGE

SDS-PAGE analysis of V3S-0622-YC1902 in non-reduced (lane 1) and β-mercaptoethanol-reduced (lane 2) conditions. Gel stained for 30 minutes with Coomassie Blue. As a result of different β-mercaptoethanol-reduced proteins (Heavy chain and Light chain) migrate as about 50 kDa and 25 kDa, respectively.

Figure 1 Anti-IL1B Monoclonal Antibody (V3S-0622-YC1902) in SDS-PAGE

SEC-HPLC

Figure 2 Anti-IL1B Monoclonal Antibody (V3S-0622-YC1902) in SEC-HPLC

The purity of V3S-0622-YC1902 was greater than 95% as determined by SEC-HPLC.

Figure 2 Anti-IL1B Monoclonal Antibody (V3S-0622-YC1902) in SEC-HPLC

Figure 3 Anti-IL1B Monoclonal Antibody (V3S-0622-YC1902) in WB

Western blot analysis of V3S-0622-YC1902 was performed by loading Recombinant Human IL1 Beta.

Lane 1: Non-Reducing Antigen (1 μg)
Lane 2: Reducing Antigen (1 μg)

Figure 3 Anti-IL1B Monoclonal Antibody (V3S-0622-YC1902) in WB

ELISA

Figure 4 Anti-IL1B Monoclonal Antibody (V3S-0622-YC1902) in ELISA

ELISA analysis of V3S-0622-YC1902 was performed by coating with Recombinant Human IL1 Beta.

Figure 4 Anti-IL1B Monoclonal Antibody (V3S-0622-YC1902) in ELISA

Application	WB; ELISA; IP; FC; FuncS; Neut; IF
Application Notes	The antibody is recommended for detection of IL1B by WB, ELISA, IP, FC, FuncS, Neut, IF assays.

ELISA	Enzyme-Linked Immunosorbent Assay Protocol
WB	Western Blot Protocol
FC	Flow Cytometry Protocol

Target	IL1B
Alternative Name	Hematopoietin 1; IFN beta inducing factor; IL 1; IL 1 beta; IL 1B; IL-1 beta; IL1 BETA; IL1F2; Interleukin 1 beta; Interleukin 1 beta precursor; Interleukin-1 beta; LAF; OAF; Osteoclast activating factor; OTTHUM
Gene ID	3553
Research Area	Cardiovascular

Anti-IL1B Neutralizing Antibody (V3S-0622-YC1902) (CAT#: V3S-0622-YC1902)

Summary

Property

Applications

Protocols

Target

Tested Data

Anti-IL1B Neutralizing Antibody (V3S-0622-YC1902) (CAT#: V3S-0622-YC1902)

Summary

Property

Applications

Protocols

Target

Tested Data

Isotype Control

Secondary Antibody

Related Products